The Bill & Melinda Gates Foundation has made a commitment to invest $52 million in CureVac, a leading clinical-stage biopharmaceutical company specializing in mRNA-based vaccine technologies. The foundation will also provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary messenger RNA (mRNA) platform.

CureVac is pioneering the use of natural and chemically unmodified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.

press release
article in Fierce Biotech